Stay updated with breaking news from Phase 3. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biosenic, a company specializing in serious autoimmune and inflammatory diseases and cell therapy, has secured funding from Singapore-based TrialCap, in a bid to accelerate its phase 3 clinical development.
Shares of Invivyd, Inc. (IVVD) are up 148% on Monday following the announcement of positive initial results from the CANOPY Phase 3 pivotal clinical trial of VYD222.
Phase 3 data presented at ASH 2023 show the gene therapy significantly reduced annualized bleeding rates and the number of total bleeds.
Biosenic, a company specializing in serious autoimmune and inflammatory diseases and cell therapy, has secured funding from Singapore-based TrialCap, in a bid to accelerate its phase 3 clinical development.
Results showed treatment with iptacopan through 48 weeks caused hemoglobin-level increases, blood transfusion avoidance, and reductions in patient-reported fatigue.